@entity1 enterocytes express apolipoprotein (apo)B-48, which is produced after posttranscriptional RNA editing of the nuclear @entity9331 transcript by the catalytic deaminase @entity19081 . Earlier studies in @entity19081 -/- @entity19 revealed an @entity9331 -only lipoprotein profile but no gross defects in @entity412 absorption. However, @entity154 may have been obscured by the mixed genetic background. In addition, the intrinsic susceptibility to proteolytic degradation of intestinal @entity9331 and @entity9331 has been questioned. Accordingly, we examined @entity412 absorption, intestinal @entity9331 expression, and lipoprotein secretion in @entity19081 -/- @entity19 backcrossed into a C57BL/6 background. Inbred @entity19081 -/- @entity19 absorb @entity412 normally, yet secrete @entity412 -rich lipoproteins more slowly than wild-type congenic controls. There was comparable induction of @entity9331 synthesis in response to fat feeding in both genotypes, but @entity9331 was preferentially retained and more extensively degraded than @entity9331 . By contrast, synthesis, secretion, and content of @entity36342 were indistinguishable in @entity19081 -/- and wild-type @entity19 with 100% recovery, suggesting no degradation of this apoprotein in either genotype. Newly secreted lipoproteins from isolated enterocytes of wild-type @entity19 revealed @entity9331 in both high-density lipoproteins and very low-density lipoproteins. By contrast, @entity19081 -/- @entity19 secreted @entity9331 -containing particles that were almost exclusively in the low and very low-density lipoproteins range with no @entity9331 -containing high-density lipoproteins. These studies establish the existence of preferential degradation of intestinal @entity9331 and @entity154 in @entity412 secretion in @entity19081 -/- @entity19 , coupled with a shift to the production of larger particles, findings that suggest an important divergence in intestinal lipoprotein assembly pathways with the different isoforms of @entity9331 .

Intestinal lipoprotein assembly in XXXX -/- @entity19 reveals subtle alterations in @entity412 secretion coupled with a shift to larger lipoproteins.

@entity1 :: ('9606', 'Species') :: ['Mammalian'] @entity154 :: ('MESH:D000013', 'Disease') :: ['subtle defects'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity19081 :: ('11810(Tax:10090)', 'Gene') :: ['apobec-1'] @entity9331 :: ('238055(Tax:10090)', 'Gene') :: ['apoB', 'apoB-100', 'apoB-48'] @entity36342 :: ('11808(Tax:10090)', 'Gene') :: ['apo A-IV'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']
@entity19081 :: (11810(Tax:10090),Gene) :: ['apobec-1']
